Phase 1 data indicate invikafusp alfa's potential as a precision cancer immunotherapeutic in solid tumors that have ...

Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for ...

Panelists discuss how to help patients weigh the risks and benefits of different treatment options for paroxysmal nocturnal hemoglobinuria (PNH), outlining tools and techniques used to ensure that ...

Panelists discuss resources and strategies to help patients and caregivers cope with the initial shock of a paroxysmal nocturnal hemoglobinuria (PNH) diagnosis, emphasizing critical points during the ...

An oncology nurse practitioner's transition from private practice to cancer research offers insights for nurses exploring new career paths within oncology.

Analysis of two trials indicates psilocybin-assisted psychotherapy may benefit the mental health of patients with cancer.

The SU2C-SARC032 study demonstrated that pembrolizumab combined with radiotherapy and surgery was well tolerated, with ...

Panelists discuss how oral and subcutaneous therapies have improved the quality of life for patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Squires sharing patient ...

Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for those with advanced, treatment-naïve disease.

A new drug application has been submitted to the FDA for dordaviprone to treat recurrent H3K27M-mutant diffuse glioma.

Panelists discuss how dermatologic toxicities from EGFR-targeted therapies can be effectively managed through a comprehensive approach combining prophylactic measures, early interventions with oral ...